LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Leung, Cheuk Lun"
  2. AU=Berman Claudia G
  3. AU=Chang Wen Xiu
  4. AU=Chen Jianchun
  5. AU="Zhou, Long" AU="Zhou, Long"
  6. AU=Bauer Michael AU=Bauer Michael
  7. AU=Clapp Benjamin
  8. AU="Makarenko, V"
  9. AU="Stahl, Anna"
  10. AU="Wa, Qingbo"
  11. AU="Annette T. Byrne"
  12. AU="Godwin Oligbu"

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging.

    Moore, Sarah J / Leung, Cheuk Lun / Norton, Heidi K / Cochran, Jennifer R

    PloS one

    2013  Band 8, Heft 4, Seite(n) e60498

    Abstract: Background: Cystine-knot miniproteins, also known as knottins, have shown great potential as molecular scaffolds for the development of targeted therapeutics and diagnostic agents. For this purpose, previous protein engineering efforts have focused on ... ...

    Abstract Background: Cystine-knot miniproteins, also known as knottins, have shown great potential as molecular scaffolds for the development of targeted therapeutics and diagnostic agents. For this purpose, previous protein engineering efforts have focused on knottins based on the Ecballium elaterium trypsin inhibitor (EETI) from squash seeds, the Agouti-related protein (AgRP) neuropeptide from mammals, or the Kalata B1 uterotonic peptide from plants. Here, we demonstrate that Agatoxin (AgTx), an ion channel inhibitor found in spider venom, can be used as a molecular scaffold to engineer knottins that bind with high-affinity to a tumor-associated integrin receptor.
    Methodology/principal findings: We used a rational loop-grafting approach to engineer AgTx variants that bound to αvβ3 integrin with affinities in the low nM range. We showed that a disulfide-constrained loop from AgRP, a structurally-related knottin, can be substituted into AgTx to confer its high affinity binding properties. In parallel, we identified amino acid mutations required for efficient in vitro folding of engineered integrin-binding AgTx variants. Molecular imaging was used to evaluate in vivo tumor targeting and biodistribution of an engineered AgTx knottin compared to integrin-binding knottins based on AgRP and EETI. Knottin peptides were chemically synthesized and conjugated to a near-infrared fluorescent dye. Integrin-binding AgTx, AgRP, and EETI knottins all generated high tumor imaging contrast in U87MG glioblastoma xenograft models. Interestingly, EETI-based knottins generated significantly lower non-specific kidney imaging signals compared to AgTx and AgRP-based knottins.
    Conclusions/significance: In this study, we demonstrate that AgTx, a knottin from spider venom, can be engineered to bind with high affinity to a tumor-associated receptor target. This work validates AgTx as a viable molecular scaffold for protein engineering, and further demonstrates the promise of using tumor-targeting knottins as probes for in vivo molecular imaging.
    Mesh-Begriff(e) Agatoxins/chemistry ; Agatoxins/genetics ; Amino Acid Substitution ; Animals ; Carbocyanines/chemistry ; Cysteine/genetics ; Cystine Knot Motifs ; Female ; Fluorescent Dyes/chemistry ; Humans ; Integrin alphaVbeta3/metabolism ; K562 Cells ; Mice ; Mice, Nude ; Mutagenesis, Site-Directed ; Neoplasm Transplantation ; Neoplasms/diagnosis ; Protein Binding ; Protein Engineering ; Protein Folding
    Chemische Substanzen Agatoxins ; Carbocyanines ; Fluorescent Dyes ; Integrin alphaVbeta3 ; Cysteine (K848JZ4886)
    Sprache Englisch
    Erscheinungsdatum 2013-04-03
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0060498
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.

    Eskiocak, Ugur / Guzman, Wilson / Wolf, Benjamin / Cummings, Christine / Milling, Lauren / Wu, Hsin-Jung / Ophir, Michael / Lambden, Conner / Bakhru, Pearl / Gilmore, Dana C / Ottinger, Samantha / Liu, Lucy / McConaughy, William K / He, Sunny Q / Wang, Chao / Leung, Cheuk Lun / Lajoie, Jason / Carson, William F / Zizlsperger, Nora /
    Schmidt, Michael M / Anderson, Ana C / Bobrowicz, Piotr / Schuetz, Thomas J / Tighe, Robert

    JCI insight

    2020  Band 5, Heft 5

    Abstract: CD137 (4-1BB) is a member of the TNFR superfamily that represents a promising target for cancer immunotherapy. Recent insights into the function of TNFR agonist antibodies implicate epitope, affinity, and IgG subclass as critical features, and these ... ...

    Abstract CD137 (4-1BB) is a member of the TNFR superfamily that represents a promising target for cancer immunotherapy. Recent insights into the function of TNFR agonist antibodies implicate epitope, affinity, and IgG subclass as critical features, and these observations help explain the limited activity and toxicity seen with clinically tested CD137 agonists. Here, we describe the preclinical characterization of CTX-471, a fully human IgG4 agonist of CD137 that engages a unique epitope that is shared by human, cynomolgus monkey, and mouse and is associated with a differentiated pharmacology and toxicology profile. In vitro, CTX-471 increased IFN-γ production by human T cells in an Fcγ receptor-dependent (FcγR-dependent) manner, displaying an intermediate level of activity between 2 clinical-stage anti-CD137 antibodies. In mice, CTX-471 exhibited curative monotherapy activity in various syngeneic tumor models and showed a unique ability to cure mice of very large (~500 mm3) tumors compared with validated antibodies against checkpoints and TNFR superfamily members. Extremely high doses of CTX-471 were well tolerated, with no signs of hepatic toxicity. Collectively, these data demonstrate that CTX-471 is a unique CD137 agonist that displays an excellent safety profile and an unprecedented level of monotherapy efficacy against very large tumors.
    Mesh-Begriff(e) Animals ; Antibodies, Monoclonal/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Chemical and Drug Induced Liver Injury/prevention & control ; Epitope Mapping ; Gene Expression Profiling ; HEK293 Cells ; Humans ; Immunotherapy/adverse effects ; Immunotherapy/methods ; Lymphocyte Activation ; Lymphocytes, Tumor-Infiltrating/metabolism ; Macaca fascicularis ; Mice ; Mice, Nude ; Neoplasms/immunology ; Neoplasms/therapy ; T-Lymphocytes/immunology ; Tumor Necrosis Factor Receptor Superfamily, Member 9/chemistry ; Tumor Necrosis Factor Receptor Superfamily, Member 9/immunology ; Xenograft Model Antitumor Assays
    Chemische Substanzen Antibodies, Monoclonal ; Tumor Necrosis Factor Receptor Superfamily, Member 9
    Sprache Englisch
    Erscheinungsdatum 2020-03-12
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2379-3708
    ISSN (online) 2379-3708
    DOI 10.1172/jci.insight.133647
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.

    Hastie, Kathryn M / Li, Haoyang / Bedinger, Daniel / Schendel, Sharon L / Dennison, S Moses / Li, Kan / Rayaprolu, Vamseedhar / Yu, Xiaoying / Mann, Colin / Zandonatti, Michelle / Diaz Avalos, Ruben / Zyla, Dawid / Buck, Tierra / Hui, Sean / Shaffer, Kelly / Hariharan, Chitra / Yin, Jieyun / Olmedillas, Eduardo / Enriquez, Adrian /
    Parekh, Diptiben / Abraha, Milite / Feeney, Elizabeth / Horn, Gillian Q / Aldon, Yoann / Ali, Hanif / Aracic, Sanja / Cobb, Ronald R / Federman, Ross S / Fernandez, Joseph M / Glanville, Jacob / Green, Robin / Grigoryan, Gevorg / Lujan Hernandez, Ana G / Ho, David D / Huang, Kuan-Ying A / Ingraham, John / Jiang, Weidong / Kellam, Paul / Kim, Cheolmin / Kim, Minsoo / Kim, Hyeong Mi / Kong, Chao / Krebs, Shelly J / Lan, Fei / Lang, Guojun / Lee, Sooyoung / Leung, Cheuk Lun / Liu, Junli / Lu, Yanan / MacCamy, Anna / McGuire, Andrew T / Palser, Anne L / Rabbitts, Terence H / Rikhtegaran Tehrani, Zahra / Sajadi, Mohammad M / Sanders, Rogier W / Sato, Aaron K / Schweizer, Liang / Seo, Jimin / Shen, Bingqing / Snitselaar, Jonne L / Stamatatos, Leonidas / Tan, Yongcong / Tomic, Milan T / van Gils, Marit J / Youssef, Sawsan / Yu, Jian / Yuan, Tom Z / Zhang, Qian / Peters, Bjoern / Tomaras, Georgia D / Germann, Timothy / Saphire, Erica Ollmann

    Science (New York, N.Y.)

    2021  Band 374, Heft 6566, Seite(n) 472–478

    Abstract: Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Multiple mutations in SARS-CoV-2 that could impair antibody defenses ... ...

    Abstract Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Multiple mutations in SARS-CoV-2 that could impair antibody defenses propagated in human-to-human transmission and spillover or spillback events between humans and animals. To develop prevention and therapeutic strategies, we formed an international consortium to map the epitope landscape on the SARS-CoV-2 spike protein, defining and structurally illustrating seven receptor binding domain (RBD)–directed antibody communities with distinct footprints and competition profiles. Pseudovirion-based neutralization assays reveal spike mutations, individually and clustered together in variants, that affect antibody function among the communities. Key classes of RBD-targeted antibodies maintain neutralization activity against these emerging SARS-CoV-2 variants. These results provide a framework for selecting antibody treatment cocktails and understanding how viral variants might affect antibody therapeutic efficacy.
    Mesh-Begriff(e) Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/therapeutic use ; Antibodies, Viral/immunology ; Antibodies, Viral/therapeutic use ; Antigens, Viral/chemistry ; Antigens, Viral/immunology ; COVID-19/therapy ; Epitope Mapping ; Humans ; Immunodominant Epitopes/chemistry ; Immunodominant Epitopes/immunology ; Protein Binding ; Protein Domains ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/immunology
    Chemische Substanzen Antibodies, Neutralizing ; Antibodies, Viral ; Antigens, Viral ; Immunodominant Epitopes ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
    Sprache Englisch
    Erscheinungsdatum 2021-09-23
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 128410-1
    ISSN 1095-9203 ; 0036-8075
    ISSN (online) 1095-9203
    ISSN 0036-8075
    DOI 10.1126/science.abh2315
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang